SEC Form 4 · accession 0001209191-18-035238
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hung Do
Officer — Chief Science Officer
Period of report
Jun 1, 2018
Accepted (ET)
Jun 4, 2018 · 5:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 1, 2018 | S | 25,000 | $16.72 | D | 396,771 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale of common stock was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2018.
- F2This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $16.49 to $17.08. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.